💊 الأدوية من أ إلى ي 🧬 الأهداف 🛠 الأدوات 📚 الأدلة
جميع الأدوية تصنيفات الأدوية المجالات العلاجية الآثار الجانبية
الأدلة المسرد الجدول الزمني
المقارنات مسارات الأدوية عائلات الأدوية
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Tecovirimat

CHEMBL1257073 Phase 4 معتمد Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
376.3 g/mol
LogP
2.6
Phase
4

Tecovirimat is an antiviral agent that inhibits the VP37 protein of orthopoxviruses, blocking the wrapping of intracellular mature virions and thereby preventing efficient spread of the virus between cells and to extracellular environments. It is approved for the treatment of smallpox and has been used under emergency authorization for mpox (monkeypox), representing a key countermeasure in orthopoxvirus preparedness. Its highly selective mechanism targets a viral protein with no human homolog, providing a favorable safety profile.

الوزن الجزيئي

376,3000 g/mol

LogP

2,60

TPSA

66,50 Ų

قاعدة ليبينسكي للخمسة

ناجح

Pharmacokinetics (PK)

Pharmacodynamics (PD)

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
O=C(NN1C(=O)[C@@H]2[C@@H]3C=C[C@@H]([C@H]4C[C@@H]34)[C@@H]2C1=O)c1ccc(C(F)(F)F)cc1

                

                

                
                

                    
InChI

                    
InChI=1S/C19H15F3N2O3/c20-19(21,22)9-3-1-8(2-4-9)16(25)23-24-17(26)14-10-5-6-11(13-7-12(10)13)15(14)18(24)27/h1-6,10-15H,7H2,(H,23,25)/t10-,11+,12+,13-,14-,15+

                

                

                

                    
                    

                        
Molecular Formula

                        
C19H15F3N2O3

                    

                    
                    

                        
HBD / HBA

                        
1 / 6

                    

                    
                    

                        
الروابط القابلة للدوران

                        
1

                    

                    
                    
                    

                        
الذرات الثقيلة

                        
27

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
الأسئلة الشائعة

                

                    
                    

                        
                        

                            
Tecovirimat is an antiviral agent that inhibits the VP37 protein of orthopoxviruses, blocking the wrapping of intracellular mature virions and thereby preventing efficient spread of the virus between cells and to extracellular environments. It is approved for the treatment of smallpox and has been used under emergency authorization for mpox (monkeypox), representing a key countermeasure in orthopoxvirus preparedness. Its highly selective mechanism targets a viral protein with no human homolog, providing a favorable safety profile.

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Tecovirimat is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1257073.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 16124688.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
إخلاء المسؤولية الطبية

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.